Search clinical trials for: Engerix B

Total 7094 results

GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
Shaare Zedek Medical Center

Terminated

Response to Hepatitis B Vaccine in Celiac Disease Patients

Celiac Disease

Israel
GlaxoSmithKline

Completed

Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y

Hepatitis B
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

Hepatitis B
VBI Vaccines Inc.

Completed

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Hepatitis B

Russian Federation
GlaxoSmithKline

Completed

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Hepatitis B

Belgium
Shaare Zedek Medical Center

Unknown

Comparison of Engerix B Vaccine Versus Sci-B-Vac Vaccine in Celiac Patients

Celiac Disease

Israel
GlaxoSmithKline

Completed

Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region

Malaria

Mozambique
Tel-Aviv Sourasky Medical Center

Unknown

Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease Patients

Hepatitis B | Chronic Kidney Disease

Israel
Emergent BioSolutions

Terminated

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years

Hepatitis B

Spain, Czech Republic, Malaysia
GlaxoSmithKline

Completed

Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine

Hepatitis B

Germany, Belgium
GlaxoSmithKline

Completed

Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.

Hepatitis B

Thailand
Hui Zhuang
Guangxi Center for Disease Control and Prevention

Completed

Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students

Immune Response | Hepatitis B | Seroprevalence

China
GlaxoSmithKline

Completed

Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine

Hepatitis B

Australia, Belgium
University of Surrey

Completed

A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines

Hepatitis B

United Kingdom
Pontificia Universidad Catolica de Chile

Not yet recruiting

Hepatitis B en Haitian Immigrants in Chile: Molecular Characterization and Determination of Vaccine Response

Hepatitis B
GlaxoSmithKline

Completed

Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine.

Hepatitis B

Thailand
Dynavax Technologies Corporation

Completed

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

Chronic Kidney Disease

United States
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Hepatitis B

Belgium
University of Oxford

Completed

Observational Study of Immune Response to Hepatitis B Childhood Booster

Healthy

United Kingdom
Dynavax Technologies Corporation

Completed

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease

United States
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Healthy

United States
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

End Stage Renal Disease

Germany
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute

Not yet recruiting

A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection (HBV003)

Chronic Hepatitis b

Australia
GlaxoSmithKline

Completed

LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

Hepatitis B

Thailand
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

Healthy

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Hepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type b

South Africa
Dynavax Technologies Corporation

Completed

Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine

Hepatitis B

Germany, Canada
Merck Sharp & Dohme LLC

Completed

A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

Hepatitis B
GlaxoSmithKline

Completed

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

Hepatitis B | Hepatitis A

Germany, Belgium, Czechia
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA

Hepatitis B

Italy
VBI Vaccines Inc.

Completed

A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults

Hepatitis B

Vietnam
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

Hepatitis B

Germany
GlaxoSmithKline

Completed

Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control

Hepatitis B
GlaxoSmithKline

Completed

Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants

Malaria | Malaria Vaccines

Tanzania
Sanofi Pasteur, a Sanofi Company
Merck Sharp & Dohme LLC

Completed

Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®

Hepatitis B | Pertussis | Tetanus | Diphtheria | Polio

Canada
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

Hepatitis B
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

Hepatitis B

Austria
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Immunologic Memory (Supp. of ATN 024)

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

Hepatitis B
Baylor College of Medicine
Centers for Disease Control and Prevention

Unknown

Adolescents' Response to Hepatitis B Vaccine Booster Dose (REACH)

Hepatitis B

United States
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Infections, Papillomavirus

Finland
GlaxoSmithKline

Completed

Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults

Hepatitis B

Austria, Belgium, Denmark, Iceland
Immutep S.A.S.
SGS Aster-Cephac (CRO)

Completed

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

Healthy

France
GlaxoSmithKline

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

Hepatitis B

Austria
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule

Hepatitis B | Pertussis | Diphtheria | Polio

Turkey

3

Subscribe